Compoferron is a brand-new product with improved physiological iron absorption properties. It retains the ability to excrete toxic metal ions from the body.
All components are approved for use as pharmaceutical products.
The new Compoferron product offers a combined effect of antianemic agents and antidotes for heavy metal/cesium radionuclide poisoning.
According to the World Health Organization (WHO), 1.8 billion people all over the world suffer from iron deficiency anemia. According to WHO, iron deficiency was found in more than 3.6 billion people whereas iron deficiency anemia (IDA) was found in almost 1.8 billion people, which makes this pathology as one of the most common medical and social problems.
Compoferron is iron/potassium ferrocyanide which is chemically bound to microcellulose using an original technology and contains the physiologically required amount of iron. The original pharmaceutical formulation (КFe[Fe(CN)6] + FeSO4) contains three forms of iron.
All Compoferron components are approved for use as pharmaceutical products. BIFEGE® which was successfully used for veterinary purposes for a long time can be considered the original version and the analog of Compoferron in terms of functionality.
Historically, ferrocinum-containing products were considered a traditional drug for radioactive incident response. They were used to remove radioactive cesium from the body and treat toxic metal poisonings.
In this respect, ferrocinum-containing products may be regarded as orphan drugs, that is, pharmaceutical agents of critical importance that have been developed specifically to treat a rare medical condition.
Ferrocinum® is the Russian ferrocinum-containing product specifically used for this purpose. It is produced by the Federal State Unitary Enterprise Scientific and Production Center Farmzashchita. The substance for Ferrocinum® is (Reg. No. LSR-010485/08) is made by Scientific Production Enterprise EKSORB Ltd.
Iron/potassium ferrocyanide in the product composition ensures regulated absorption of the required amount of iron in the human body by binding physiologically excessive iron ions into non-soluble iron ferrocyanide. Moreover, the composition offers additional capabilities (for Compoferron®) for removing radionuclides and toxic heavy metals, such as thallium, lead, cadmium, mercury, arsenic, etc., from the human body. Microcellulose in the product formula has regenerative properties and prevents iron (II) oxidation. In addition, the composition includes potassium sulfate to regulate bowel movements and prevent constipation.